Author

Jonathan Spergel

Solving the Riddle of Disease Control in EoE (Sanofi)
Solving the Riddle of Disease Control in EoE (Sanofi)

Jonathan Spergel

DUPILUMAB IMPROVES HISTOLOGICAL AND ENDOSCOPIC FEATURES OF EOSINOPHILIC OESOPHAGITIS IN CHILDREN AGED 1–11 YEARS IN THE PHASE 3 EOE KIDS TRIAL
DUPILUMAB IMPROVES HISTOLOGICAL AND ENDOSCOPIC FEATURES OF EOSINOPHILIC OESOPHAGITIS IN CHILDREN AGED 1–11 YEARS IN THE PHASE 3 EOE KIDS TRIAL

Jonathan Spergel  et al.

DUPILUMAB EFFICACY AND SAFETY IN ADULT AND ADOLESCENT PATIENTS WITH EOSINOPHILIC ESOPHAGITIS: RESULTS FROM PART A OF A RANDOMIZED, PLACEBO-CONTROLLED THREE-PART, PHASE 3 STUDY
DUPILUMAB EFFICACY AND SAFETY IN ADULT AND ADOLESCENT PATIENTS WITH EOSINOPHILIC ESOPHAGITIS: RESULTS FROM PART A OF A RANDOMIZED, PLACEBO-CONTROLLED THREE-PART, PHASE 3 STUDY

Jonathan Spergel  et al.

DUPILUMAB IN PAEDIATRIC PATIENTS WITH EOSINOPHILIC OESOPHAGITIS – DESIGN OF A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF DUPILUMAB IN CHILDREN AGED 1–11 YEARS, WITH ACTIVE EOSINOPHILIC OESOPHAGITIS
DUPILUMAB IN PAEDIATRIC PATIENTS WITH EOSINOPHILIC OESOPHAGITIS – DESIGN OF A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF DUPILUMAB IN CHILDREN AGED 1–11 YEARS, WITH ACTIVE EOSINOPHILIC OESOPHAGITIS

Jonathan Spergel  et al.

DUPILUMAB EFFICACY AND SAFETY UP TO 52 WEEKS IN ADULT AND ADOLESCENT PATIENTS WITH EOSINOPHILIC ESOPHAGITIS: RESULTS FROM PART A AND C OF A RANDOMIZED, PLACEBO-CONTROLLED, THREE-PART, PHASE 3 LIBERTY EOE TREET STUDY
DUPILUMAB EFFICACY AND SAFETY UP TO 52 WEEKS IN ADULT AND ADOLESCENT PATIENTS WITH EOSINOPHILIC ESOPHAGITIS: RESULTS FROM PART A AND C OF A RANDOMIZED, PLACEBO-CONTROLLED, THREE-PART, PHASE 3 LIBERTY EOE TREET STUDY

Jonathan Spergel  et al.

Item 1 - 5 / 5
1